Bayer-to-manufacture-mRNA-vaccine-in-Germany
(Source: Bayer Company News)
Source: Bayer Company News - February 1, 2021 Category: Pharmaceuticals Source Type: news

Ukko-secures-USD-million-Series-B-funding-Leaps-Bayer-overcome-allergies-sensitivities
Top industry leaders and venture firms unite behind Ukko’s efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten (Source: Bayer Company News)
Source: Bayer Company News - January 27, 2021 Category: Pharmaceuticals Source Type: news

US-FDA-approves-vericiguat-for-patients-with-symptomatic-chronic-heart-failure
Vericiguat (Verquvo ® ) is the first soluble guanylate cyclase (sGC) stimulator to be approved for the treatment of symptomatic chronic heart failure / Vericiguat works on a pathway not currently targeted by existing heart failure treatments (Source: Bayer Company News)
Source: Bayer Company News - January 20, 2021 Category: Pharmaceuticals Source Type: news

Bayer-transforms-pharma-business-through-breakthrough-innovation-in-healthcare
Emerging leadership in field of cell and gene therapies / Accelerating breakthrough innovation for patients / Innovation in field of digital health solutions to become key pillar of Bayer’s pharmaceutical business empowering patients with Integrated Care offerings / Promising development portfolio with more than 50 projects in clinical development phases (Source: Bayer Company News)
Source: Bayer Company News - January 13, 2021 Category: Pharmaceuticals Source Type: news

US-FDA-grants-priority-review-New-Drug-Application-finerenone-treat-patients-chronic-kidney-disease
(Source: Bayer Company News)
Source: Bayer Company News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Supervisory-Board-Bayer-AG-appoints-Sarena-Lin-Board-Management-Chief-Transformation-Talent-Officer
(Source: Bayer Company News)
Source: Bayer Company News - January 11, 2021 Category: Pharmaceuticals Source Type: news

Bayer-issues-new-senior-bonds-with-a-volume-of-4-billion-euros
Issuance of four tranches with maturities between 4 and 15 years was substantially oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - January 7, 2021 Category: Pharmaceuticals Source Type: news

CureVac-and-Bayer-join-forces-on-COVID-19-vaccine-candidate-CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer ´ s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses (Source: Bayer Company News)
Source: Bayer Company News - January 7, 2021 Category: Pharmaceuticals Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T
Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy / Bayer to enter CAR-T cell therapy space and expand oncology development pipeline with groundbreaking technology / Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy / Partnership will focus on the next generation, off-the-shelf T-cell immunotherapy ATA3271 for treatment of high mesothelin-expressing tumors / Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-...
Source: Bayer Company News - December 7, 2020 Category: Pharmaceuticals Source Type: news

Third-quarter-of-2020-
Group sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering – higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros – impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash flow falls by 2.1 percent to 1.237 billion ...
Source: Bayer Company News - November 3, 2020 Category: Pharmaceuticals Source Type: news

Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularization
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure, ...
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine publishes final overall survival data for Nubeqa ™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer (for specialized target groups only)
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases
Drug Discovery partnership and equity investment led by Leaps by Bayer in Series D financing round / Digitally-powered drug discovery to address fibrotic diseases with previously undiscovered mechanisms and to deliver novel therapies to patients faster (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news